These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9690974)

  • 1. How much do novel antipsychotics benefit the patients?
    Kasper S
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S71-7. PubMed ID: 9690974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel antipsychotics and negative symptoms.
    Möller HJ
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S43-7. PubMed ID: 9690970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sertindole: a review of clinical efficacy.
    Kane JM
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S59-63; discussion S63-4. PubMed ID: 9690972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the efficacy, tolerability and safety of sertindole in clinical trials.
    Perquin L; Steinert T
    CNS Drugs; 2004; 18 Suppl 2():19-30; discussion 41-3. PubMed ID: 15461313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do we need another atypical antipsychotic?
    Kasper S
    Eur Neuropsychopharmacol; 2008 Aug; 18 Suppl 3():S146-52. PubMed ID: 18511242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis.
    Azorin JM; Murteira S; Hansen K; Toumi M
    BMC Psychiatry; 2008 Mar; 8():16. PubMed ID: 18366634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-episode schizophrenia: the importance of early intervention and subjective tolerability.
    Kasper S
    J Clin Psychiatry; 1999; 60 Suppl 23():5-9. PubMed ID: 10625193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the safety and tolerability of sertindole.
    Hale AS
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S65-70. PubMed ID: 9690973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
    Kane JM; Potkin SG; Daniel DG; Buckley PF
    J Clin Psychiatry; 2011 Feb; 72(2):194-204. PubMed ID: 20673553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
    Smith RC; Leucht S; Davis JM
    Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The European Post-marketing Observational Serdolect (EPOS) Project: increasing our understanding of schizophrenia therapy.
    Wehnert A
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S27-30. PubMed ID: 9690967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case histories illustrating the utility of sertindole in clinical practice.
    Schuck P; van den Ameele H; Jaanson P; Ryckmans V; Hawley C
    CNS Drugs; 2004; 18 Suppl 2():31-40; discussion 41-3. PubMed ID: 15461314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.
    Pezawas L; Quiner S; Moertl D; Tauscher J; Barnas C; Küfferle B; Wolf R; Kasper S
    Int Clin Psychopharmacol; 2000 Jul; 15(4):207-14. PubMed ID: 10954060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The promise of new drugs for schizophrenia treatment.
    Tamminga CA
    Can J Psychiatry; 1997 Apr; 42(3):265-73. PubMed ID: 9114942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of atypical antipsychotics in the management of schizophrenia.
    Campbell M; Young PI; Bateman DN; Smith JM; Thomas SH
    Br J Clin Pharmacol; 1999 Jan; 47(1):13-22. PubMed ID: 10073734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The scourge of EPS: have atypical antipsychotics solved the problem?
    J Clin Psychiatry; 2000 Dec; 61(12):955-62. PubMed ID: 11206607
    [No Abstract]   [Full Text] [Related]  

  • 18. Sertindole in schizophrenia: efficacy and safety issues.
    Muscatello MR; Bruno A; Micali Bellinghieri P; Pandolfo G; Zoccali RA
    Expert Opin Pharmacother; 2014 Sep; 15(13):1943-53. PubMed ID: 25084209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging treatments in the management of schizophrenia - focus on sertindole.
    Muscatello MR; Bruno A; Pandolfo G; Micò U; Settineri S; Zoccali R
    Drug Des Devel Ther; 2010 Sep; 4():187-201. PubMed ID: 20856845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment.
    Kasper S; Möller HJ; Hale A
    Eur Arch Psychiatry Clin Neurosci; 2010 Feb; 260(1):59-68. PubMed ID: 19455275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.